X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the license agreement, Takeda will have the exclusive right to develop and commercialize nucleic acidbased therapies using Luxna XNAs Technology for specified targets.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $86.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 24, 2022
Details:
The amended agreement grants Aligos exclusive rights to use Luxna’s technology to target the genomes of certain families of respiratory viruses, including Coronaviridae, which includes SARS-CoV-2.
Lead Product(s): Antisense oligonucleotide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Aligos Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 15, 2020
Details:
Luxna Biotech will use this capital to drive collaboration with pharmaceutical companies and academia by strengthening its platform technologies for oligonucleotide therapeutics.
Lead Product(s): Oligonucleotide
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Summit Pharmaceuticals Europe Srl
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing February 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
